2023 Clinical Trials DEA 
SpeedWeed
MAY 15, 2021
A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. If all goes well, the FDA could legalize MDMA-assisted therapy next year, which would make it legally available starting in 2023. Image via.
Cannabis Law Report
OCTOBER 4, 2021
A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. Schedule I.
Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. Berra Yazar-Klosinski, Ph.D.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. As previously mentioned, clinical studies are promising, including a Phase 3 trial (the last step before submitting an NDA) completed last November. [9] Clinical Trials and Human Subject Protections. Challenges.
Cannabis Law Report
AUGUST 18, 2022
Study and development of these treatments remain challenging as psilocybin, MDMA, DMT and LSD are all listed as DEA Schedule I drugs. It is anticipated that MDMA will receive FDA approval for PTSD by the end of 2023, and that psilocybin approval will follow. However, change appears imminent.
Cannabis Law Report
DECEMBER 21, 2021
It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).
Expert insights. Personalized for you.
52 
Let's personalize your content